@article{bc1ba0e2e0e24bed932abaf0efa63611,
title = "Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop",
author = "P. Lorigan and Eggermont, \{A. M.M.\}",
note = "Funding Information: PL has been paid advisor/speaker for BMS, MSD, Novartis, Amgen, Roche, Neracare, Pierre Fabre, received research funding from BMS and received support for travel MSD, BMS. AMME received honoraria for SAB or IDMC from BMS, CatalYm, CellDex, Ellipses, GSK, Incyte, IO Biotech, ISA Pharmaceuticals, MSD, Novartis, Pfizer, Polynoma, Sanofi, Sellas, SkylineDx and received speaker fees from MSD, Novartis. Stock Options: RiverD, SkylineDX.",
year = "2019",
month = jul,
day = "1",
doi = "10.1093/annonc/mdz182",
language = "English",
volume = "30",
pages = "1038--1040",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Ltd.",
number = "7",
}